MOUNTAIN VIEW, Calif.,
Aug. 9, 2012 /PRNewswire/ -- MAP
Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the
Company will present at the following investor conferences:
Canaccord Genuity 32nd Annual Growth Conference
Thursday, August 16, at 11:30 a.m. ET in Boston
Stifel Nicolaus Annual Healthcare Conference
Thursday, September 6, at
8:00 a.m. ET in Boston
A live webcast of each presentation will be available on the
Investor Relations section of MAP Pharmaceuticals' website at
http://www.mappharma.com. A replay also will be available within 24
hours for seven days following each presentation.
About MAP Pharmaceuticals
MAP Pharmaceuticals is a biopharmaceutical company focused on
developing and commercializing new therapies to address undermet
patient needs in neurology. The Company is developing LEVADEX®, an
orally inhaled investigational drug for the acute treatment of
migraine. The U.S. Food and Drug Administration (FDA) reviewed the
New Drug Application (NDA) for LEVADEX and on March 26, 2012, the Company received a Complete
Response letter with respect to this NDA. The Company completed an
End-of-Review meeting with the FDA and plans to resubmit in the
late third quarter/early fourth quarter 2012 timeframe. MAP
Pharmaceuticals has entered into a collaboration agreement with
Allergan, Inc. to co-promote LEVADEX to neurologists and pain
specialists in the U.S. and Canada. The Company also applies its
proprietary drug particle and inhalation technologies to generate
new pipeline opportunities by enhancing the therapeutic benefits of
proven drugs, while minimizing risk by capitalizing on their known
safety, efficacy and commercialization history. Additional
information about MAP Pharmaceuticals can be found at
http://www.mappharma.com.
CONTACT:
Lisa Borland
MAP Pharmaceuticals, Inc.
650-386-3122
lborland@mappharma.com
SOURCE MAP Pharmaceuticals, Inc.